Synonyms: SIM-0417 | SIM0417 | SSD-8432 | SSD8432
simnotrelvir is an approved drug (China NMPA (2023))
Compound class:
Synthetic organic
Comment: Simnotrelvir (SIM0417) is an oral inhibitor of SARS-CoV-2 Mpro [2].
|
|
No information available. |
Summary of Clinical Use ![]() |
Clinical trials demonstrated that simnotrelvir/ritonavir was effective and well tolerated in the treatment of COVID-19. Simnotrelvir was approved by the Chinese regulatory authorities in January 2023. It is co-packaged with ritonavir tablets. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05506176 | A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 | Phase 2/Phase 3 Interventional | Jiangsu Simcere Pharmaceutical Co., Ltd. | ||
NCT05369676 | To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 | Phase 1/Phase 2 Interventional | Jiangsu Simcere Pharmaceutical Co., Ltd. | 1 |